All In Biotech

Drug Trial Radar · NCT00891735

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Jan 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,097 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,097

Actual

Start

Jul 2009

Primary completion

Aug 2011

Study completion Aug 2012

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 1, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Results are presented for the first 12 months of the study.

Conditions

  • Age-related Macular Degeneration

Interventions

  • RanibizumabDrug

    Sterile solution for intravitreal injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12Time frame: Baseline to Month 12

Locations

99 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Arcadia, California

  • Site not named

    Beverly Hills, California

  • Site not named

    Campbell, California

  • Site not named

    Chico, California

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Mountain View, California

  • Site not named

    Oakland, California

  • Site not named

    Palm Desert, California

  • Site not named

    Poway, California

  • Site not named

    Sacramento, California

  • Site not named

    San Francisco, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Ana, California

  • Site not named

    Santa Barbara, California

  • Site not named

    Torrance, California

  • Site not named

    Ventura, California

  • Site not named

    Westlake Village, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Golden, Colorado

  • Site not named

    Danbury, Connecticut

  • Site not named

    Hamden, Connecticut

  • Site not named

    New Haven, Connecticut

  • Site not named

    New London, Connecticut

  • Site not named

    Altamonte Springs, Florida

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Palm Beach Gardens, Florida

  • Site not named

    Pensacola, Florida

  • Site not named

    Stuart, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Winter Haven, Florida

  • Site not named

    Augusta, Georgia

  • Site not named

    ‘Aiea, Hawaii

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.